CD4 and diffuse large B-cell lymphoma: For instance, a clinical trial with JCAR017 (liso-cel, FDA approved for r/r DLBCL) has been recommended to use a fixed ratio of CD8 to CD4 cells for B cell lymphoma (NCT04245839) [44].